![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, May 04, 2008 3:16:00 PM
Fri May 2, 2008 7:00pm EDT
By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters) - A new type of treatment that trains immune system cells to better recognize the AIDS virus may help control the deadly and incurable infection, Australian researchers reported on Friday.
Tests on monkeys infected with a similar virus shows the treatment controlled the infection, although it does not cure it, and tests are already planned in people.
The treatment is called OPAL, for Overlapping Peptide-pulsed Autologous Cells, and would be categorized as an immunotherapy technique, or a so-called therapeutic vaccine, Stephen Kent of the University of Melbourne and colleagues said.
Writing in the Public Library of Science journal PLoS Pathogens, they said the treatment involves mixing a patient's own blood cells with tiny bits of protein from the virus.
These cells are then re-infused into the patient.
"Levels of virus in vaccinated monkeys were 10-fold lower than in controls, and this was durable for over one year after the initial vaccinations," they wrote.
"The immunotherapy resulted in fewer deaths from AIDS. We conclude this is a promising immunotherapy technique. Trials in HIV-infected humans of OPAL therapy are planned."
The AIDS virus infects more than 33 million people globally and has killed 25 million since it was identified in the 1980s.
While there is no cure and no vaccine, cocktails of drugs can control the virus. But they have side-effects, are expensive and eventually often stop working.
Kent's team took small bits of the virus called peptides and placed them in lab dishes with both whole blood and isolated immune system cells.
This helped train the cells to recognize the virus and attack it more effectively, they wrote in the paper, freely available here
The macaque monkeys were infected with a related virus called SIV or simian immunodeficiency virus.
HIV is tricky to treat because it attacks the immune system. It specifically goes after immune cells called CD4 T cells, the very cells that are supposed to attack and kill viruses.
"Virus-specific CD4 T cells are typically very weak in HIV-infected humans or SIV-infected macaques; dramatic enhancement of these cells were induced by OPAL immunotherapy and this may underlie its efficacy," they wrote.
The treatment appears to work best if started right after someone becomes infected.
"Although it may be challenging to identify humans within three weeks of infection, this is when HIV-1 subjects typically present (show up at a doctors office) with acute infection," they wrote.
(Editing by Todd Eastham)
BECAUSE YOU CAN READ THIS, THANK A TEACHER. BECAUSE IT'S IN ENGLISH, THANK A SOLDIER.
Recent GOVX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/01/2024 08:12:29 PM
- GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review • GlobeNewswire Inc. • 07/31/2024 02:15:52 PM
- GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review • GlobeNewswire Inc. • 07/31/2024 01:00:00 PM
- GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 • GlobeNewswire Inc. • 07/30/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/22/2024 08:21:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:02:25 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/12/2024 02:12:15 PM
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine • GlobeNewswire Inc. • 04/04/2024 04:30:00 PM
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GeoVax to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:13:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/11/2024 04:15:24 AM
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/01/2024 09:08:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:14 PM
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:41:26 PM
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 02:00:00 PM
- GeoVax to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/19/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:25 PM
- GeoVax Announces Multiple Patent Issuances and Allowances • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM